A significant number of non-small cell lung cancer patients (NSCLC) patients miss out on optimal care due to gaps in biomarker testing, socioeconomic barriers, and incomplete patient journey data.
A new eBook from PurpleLab and MedCity News discusses how real-world data (RWD) can illuminate hidden obstacles in the NSCLC patient journey. This can include transportation access to disparities in molecular testing. States have passed a variety of legislation requiring that insurance companies cover biomarker testing. This can lead to earlier detection and improve the effectiveness of more targeted interventions and equitable outcomes.
Leveraging RWD and SDOH insights leads to more inclusive clinical trials, better patient recruitment, and therapies that serve a broader, more diverse patient population.
To download the eBook, Eliminating Blind Spots in the Non-Small Cell Lung Cancer Patient Journey with RWD, fill in the form below.